Grant projects – fostering innovation and collaboration

Miltenyi Biotec is deeply committed to empowering research and advancing therapy. For us this means that we are part of the scientific community, contributing to more than 100 national and international grant projects since the foundation of our company.

Here we present current examples of our cutting-edge collaborations funded by EU and national sources.

Grant project highlights

PiCoP – translating the concept of targeting individual cancer mutations into clinical application

CARAT – Chimeric Antigen Receptors (CARs) for Advanced Therapies

CD20 CAR-TIME – First German CAR T cell trial against solid tumors

ImmunePredict – novel tools to predict effectiveness of immune-checkpoint-inhibitors

Funding agencies

Federal Ministry of Education and Research

CD20 CAR-TIME
CD20 CAR transduced T cells for individualized melanoma therapy
Fkz 01EK1507A

ART4Fun
Antigen reactive T cells for diagnosis and therapy of fungus-associated diseases in high-risk patients
Fkz 03ZZ0813F

iCARE
Induced pluripotent stem cells for cellular therapy of cardiac diseases
Fkz 01EK1601D

iPStemRNA
Generation of GMP-compliant induced pluripotent stem cells from universal donors.
Sub-project: Development of prototypes and material for GMP-compliant production of iPS cells
Fkz 01EK1610C

ReSight
Generation of transplantable hiPSC-derived retinal cells for treatment of retinal degeneration
Fkz 01EK1613C

ELICIT
Advanced confocal light sheet microscopy for clinical high-throughput analysis of immune cell infiltration of tumor samples.
Sub-project: Development, verification and adaptation of specific probes for light sheet microscopy
Fkz 13N14347

European Union

PROCROP
Professional cross-priming for ovary and prostate cancer
GA 635122

SCIDNET
Developing Genetic medicines for Severe Combined Immunodeficiency
GA 666908

CARAT
Chimeric Antigen Receptors for Advanced Therapies
GA 667980

PIX4LIFE
Silicon Nitride Photonic Integrated Circuit Pilot line for Life Science Applications in the Visible Range
GA 688519

Trace
Transfer of multivirus-specific T-cells following transplantation
GA 755005

MATURE-NK
Manufacturing of Tumour-Reactive Natural Killer cells
GA 765104

EUROoC
Interdisciplinary training network for advancing Organ-on-a-chip technology in Europe
GA 812954

ENDONANO
Quantitative detection of bacterial endotoxin by novel nanotechnological approaches
GA 812661

European Regional Development Fund

Mecklenburg-West Pomerania

PiCoP
Peptide-based immunization strategies for Colon and Pancreas carcinomas
TBI-V-1-243-VBU-085

MACS-MS
Analysis of biomarkers for the detection of apheresis responders and glucocorticosteroid responders in multiple sclerosis patients with acute disease relapse
TBI-V-1-269-VBU-095

North Rhine Westfalia

iCAN33
Development of an immunotherapy for acute myeloid leukaemias (AMLs) using allogeneic natural killer (NK) cells with CD33 CARs
LS-2-1-018g

ImmunePredict
Development of new predictive markers for response to immune checkpoint inhibitors of solid tumors
LS-2-1-002b

TraCAR
Non-invasive imaging of pharmacokinetics and optimisation of CAR T-cell therapies of solid tumours
LS-2-2-050a

CardioPatch
Vascularised, bioartificial heart muscle from induced pluripotent stem cells
LS-2-2-029f